{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Orantinib",
  "nciThesaurus": {
    "casRegistry": "252916-29-3",
    "chebiId": "",
    "chemicalFormula": "C18H18N2O3",
    "definition": "An orally bioavailable receptor tyrosine kinase inhibitor.  SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation.  SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.",
    "fdaUniiCode": "9RL37ZZ665",
    "identifier": "C1884",
    "preferredName": "Orantinib",
    "semanticType": "Organic Chemical",
    "subclassOf": [],
    "synonyms": [
      "3-(2,4-Dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic Acid",
      "ORANTINIB",
      "Orantinib",
      "Orantinibum",
      "SU 6668",
      "SU006668",
      "SU6668",
      "Sugen SU6668",
      "TSU 68"
    ]
  }
}